History of virologic success with suppression of HIV RNA level < 50 copies/ml during the last nine months documented a minimum of two times during the last ten months or a minimum of three times during the last fifteen months while patient is receiving a HAART regiment. During the four months prior to starting Baseline, continuing through Baseline and the 64 week study period, the HAART regimen must remain unchanged and contain at least one of the following ten anti-retroviral drugs:

• Abacavir (Ziagen)
• Zidovudine (Retrovir) AZT
• Zalcitabine (Hivid) ddC
• Didanosine (Videx) ddl
• Stavudine (Zerit) d4T
• Efavirenz (Sustiva)
• Indinavir (Crixivan)
• Ritonavir (Norvir)
• Nelfinavir (Viracept)
• Amprenavir (Agenerase)

Only one HIV plasma RNA level > 50, but < 100 copies/ml is permitted during the four month period immediately prior to starting Baseline.

The following laboratory parameters within 21 days prior to treatment:

• Hemoglobin > 9.2 g/dL for men and > 8.9 g/dL for women;
• Neutrophil count > 1000;
• Platelet count > 75,000;
• AST/ALT < 4.0 x upper limit of normal (ULN);
• Serum creatinine < 1.5 x ULN or a creatinine clearance > 50 mL/min.